Clinical Trial Update: CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

This entry reports a Phase 1/2 clinical trial evaluating CBL0137 for relapsed or refractory solid tumors, including central nervous system tumors and lymphoma, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Neoplasms
• Diffuse Midline Glioma H3 K27-altered
• Lymphoma
• Malignant Solid Neoplasms

Drugs mentioned

• CBL0137 (CBL0137)

Snippet

Sponsor: Children's Oncology Group | Conditions: Diffuse Midline Glioma, H3 K27-Altered, Metastatic Malignant Neoplasm in the Central Nervous System | Phase 1, Phase 2 | Status: RECRUITING